Package Leaflet: Information for the User
Modafinilo Aurovitas 100 mg Tablets EFG
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
1.What is Modafinilo Aurovitas and what it is used for
2.What you need to know before you start taking Modafinilo Aurovitas
3.How to take Modafinilo Aurovitas
4.Possible side effects
5Storage of Modafinilo Aurovitas
6.Contents of the pack and additional information
The active ingredient in the tablets is modafinil.
Modafinilo Aurovitas can be used by adults who suffer from narcolepsy to help them stay awake.
Narcolepsy is a condition that causes excessive daytime sleepiness and a tendency to fall asleep suddenly in inappropriate situations (sleep attacks). Modafinil may improve narcolepsy and reduce the likelihood of sleep attacks, although there may be other ways to improve your condition and your doctor will inform you of them.
Do not take Modafinilo
Warnings and precautions
Consult your doctor or pharmacist before starting to take Modafinilo Aurovitas:
Other aspects to discuss with your doctor or pharmacist
Children and adolescents
Children under 18 years old should not take this medication.
Other medications and Modafinilo Aurovitas
Inform your doctor or pharmacist that you are taking, have taken recently, or may need to take any other medication, including those purchased without a prescription.
Modafinilo and other medications may affect each other, and your doctor may need to adjust the doses you are taking. It is especially important if you are taking any of the following medications with Modafinilo:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Modafinilo is suspected to cause congenital defects if taken during pregnancy.
Consult your doctor about suitable contraceptive methods for you while you are on treatment with Modafinilo (and for two months after stopping) or if you have any other questions.
Driving and operating machinery
Modafinilo may cause blurred vision or dizziness in 1 in 10 people. If you notice any of these effects or still feel drowsy while taking this medication, avoid driving vehicles or operating machinery.
Modafinilo Aurovitas contains lactose
This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Modafinilo Aurovitas contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The tablets should be swallowed whole with a little water.
Adults
The recommended dose is 200 mg per day. It can be taken once a day (in the morning) or divided into two doses per day (100 mg in the morning and 100 mg at noon).
In certain cases, your doctor may decide to increase your daily dose up to 400 mg.
Senior citizens (age 65 years or older)
The recommended dose is 100 mg per day.
Your doctor will only increase your daily dose (up to a maximum of 400 mg per day) if you do not have liver or kidney disorders.
Adults with severe liver or kidney disorders
The recommended dose is 100 mg per day.
Your doctor will regularly review the treatment to check that it is suitable for you.
If you take more Modafinilo than you should
If you have taken too many tablets, you may feel discomfort, restlessness, disorientation, confusion, agitation, anxiety, or excitement. You may also experience difficulty sleeping, diarrhea, hallucinations (sensations that are not real), chest pain, a change in the speed of your heartbeats, or an increase in your blood pressure.
Contact the nearest hospital emergency department or consult immediately with your doctor or pharmacist. Bring this leaflet and the remaining tablets with you.
In case of overdose or accidental ingestion, consult immediately with your doctor or pharmacist or call the Toxicological Information Service. Phone: 91 562 04 20 indicating the medication and the amount ingested.
If you forget to takeModafinilo
If you forget to take your medication, take the next dose at the usual time. Do not take a double dose to make up for the missed doses.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications,this medicationcan cause side effects, although not everyone will experience them.
Stop taking this medication andimmediately inform your doctorif:
Other side effects include the following:
Side effectsvery common(may affect more than 1 in 10 people):
Side effectscommon(may affect up to 1 in 10 people):
Side effectsuncommon(may affect up to 1 in 100 people):
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Use within 4 months after the first opening of the high-density polyethylene (HDPE) bottle.
This medication does not require special storage conditions.
Do not use this medication after the expiration date appearing on the label, box, and blister pack after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and unused medicines at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and unused medicines. By doing so, you will help protect the environment.
Composition of Modafinilo Aurovitas
Each tablet contains 100 mg of modafinilo.
Appearance of the product and contents of the package
This medication is presented in the form of a tablet.
Uncoated tablets of white to off-white color, in the shape of a capsule, marked with “41” on one face and “J” on the other face.
This medication is available in:
PVC/PVdC blister with aluminum foil: packaging of 1, 10, 20, 30, 50, 60, 90, 100, 120, or 500 tablets.
High-density polyethylene (PEAD) bottles with a polypropylene closure containing silica gel desiccant: packaging of 30 and 100 tablets.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Responsible manufacturer:
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
Or
Arrow Génériques
26avenue Tony Garnier,
Lyon, 69007
France
Or
Generis Farmacêutica, S.A.
Rua João de Deus 19,Venda Nova
2700-487 Amadora
Portugal
This medication is authorized in the member states of the European Economic Area with the following names:
France:MODAFINIL ARROW 100 mg, tablet
Germany:Modafinil Aurobindo 100 mg Tabletten
Netherlands:Modafinil Aurobindo 100 mg, tabletten
Spain:Modafinilo Aurovitas 100 mg comprimidos EFG
Last review date of this leaflet: February 2021
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.